Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
OS Therapies Incorporated is a pre-revenue clinical-stage biotechnology company focused on developing novel therapeutics for osteosarcoma and other bone-related cancers. With no marketed products and negative cash flow of approximately $17M annually, the company is entirely dependent on capital markets funding to advance its pipeline through clinical trials. The stock trades on binary clinical trial outcomes and financing risk.
As a clinical-stage biotech, OSTX does not currently generate revenue. The business model depends on successfully advancing drug candidates through Phase I/II/III trials, obtaining FDA approval, and either commercializing products independently or partnering with larger pharma companies for milestone payments and royalties. Value creation occurs through clinical data readouts that de-risk the pipeline. The company's extremely low current ratio (0.56) indicates immediate liquidity constraints, suggesting near-term financing needs through equity raises or partnerships.
Clinical trial data readouts and milestone achievements (patient enrollment completion, interim analyses, primary endpoint results)
FDA regulatory decisions including IND approvals, Fast Track designations, or Breakthrough Therapy status
Equity financing announcements and dilution events given current ratio of 0.56 indicating liquidity stress
Strategic partnerships or licensing deals with larger pharmaceutical companies that provide non-dilutive funding
Competitive clinical data from rival osteosarcoma programs that could validate or undermine the therapeutic approach
Binary clinical trial risk - single failed Phase II/III study could render pipeline worthless and trigger delisting given minimal cash reserves
Regulatory pathway uncertainty for rare oncology indications with small patient populations, potentially requiring expensive additional studies
Orphan drug market size limitations - osteosarcoma affects ~1,000 new US patients annually, constraining peak revenue potential even with approval
Larger oncology-focused biotechs (e.g., Blueprint Medicines, Deciphera) with superior capital resources competing for same indications
Established pharmaceutical companies potentially developing competing mechanisms of action with faster timelines to market
Academic medical centers conducting investigator-initiated trials that could establish alternative standards of care
Severe liquidity crisis indicated by 0.56 current ratio - insufficient assets to cover short-term liabilities without immediate financing
Negative $17M+ annual cash burn with no revenue requires equity raises at depressed valuations (stock down 38.6% over 1 year), causing massive dilution
Going concern risk if unable to secure financing within next 6-9 months based on current burn rate and working capital deficit
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, the company's ability to raise capital is highly sensitive to risk appetite in biotech equity markets, which correlates with broader economic conditions and investor sentiment toward speculative growth assets.
High sensitivity through valuation multiples and financing costs. Rising rates compress NPV of distant future cash flows (product approvals 3-7+ years away), making early-stage biotechs less attractive versus bonds. Higher rates also increase cost of convertible debt financing if pursued. The -786.5% ROA and negative cash flow mean the company cannot self-fund and must access capital markets where rate environment directly impacts terms and dilution.
Minimal direct credit exposure as pre-revenue company has no receivables or credit-dependent customers. However, credit market conditions affect ability to raise debt financing. Tight credit spreads enable convertible debt as less dilutive alternative to equity, while wide spreads force pure equity raises at unfavorable valuations.
momentum - Attracts highly speculative biotech investors seeking asymmetric returns from binary clinical catalysts. The 29.2% decline over 3 months and negative margins indicate this is pure venture-stage speculation, not suitable for value or income investors. Typical holders are biotech-focused hedge funds, retail momentum traders, and venture-style investors willing to accept total loss for potential 5-10x returns on positive trial data.
high - Clinical-stage biotechs with single-digit million market caps exhibit extreme volatility around data catalysts (often 50-100% single-day moves). The -38.6% one-year return, deteriorating current ratio, and imminent financing needs create elevated volatility. Stock likely trades on low volume with wide bid-ask spreads, amplifying price swings.
